Telix Pharmaceuticals (ASX:TLX) Net Income Including Noncontrolling Interests : A$49.9 Mil (TTM As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Telix Pharmaceuticals Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Telix Pharmaceuticals's Net Income Including Noncontrolling Interests for the six months ended in Dec. 2024 was A$20.3 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2024 was A$49.9 Mil.

Telix Pharmaceuticals Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Telix Pharmaceuticals's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Net Income Including Noncontrolling Interests Chart

Telix Pharmaceuticals Annual Data

Trend

Sep99

Sep00

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income Including Noncontrolling Interests

Get a 7-Day Free Trial

-44.89

-80.51

-104.08

5.21

49.92

Telix Pharmaceuticals Semi-Annual Data
	Sep00	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Net Income Including Noncontrolling Interests	Get a 7-Day Free Trial												-33.19	-14.32	19.53	29.65	20.27

Telix Pharmaceuticals Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$49.9 Mil.

Telix Pharmaceuticals Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Telix Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (ASX:TLX) » Definitions » Net Income Including Noncontrolling Interests

Comparable Companies

Traded in Other Exchanges

TLX:USA TLPPF:USA T3X:Germany

Address

55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051

Website

https://www.telixpharma.com

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.